XML 58 R46.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2025
USD ($)
numberOfSegments
Sep. 30, 2024
USD ($)
Segment Reporting [Abstract]                
Number of reportable segments | numberOfSegments             1  
Segment Reporting Information [Line Items]                
Revenues $ 529     $ 1,339     $ 13,032 $ 4,597
General and administrative 3,044     4,537     12,204 17,396
Restructuring costs 98 $ 12,400   3,625     12,636 3,625
Net Income (Loss) (7,742) $ 2,523 $ (24,526) (19,717) $ (19,796) $ (17,875) (29,745) (57,388)
Adjustments and reconciling items 0     0     0 0
Reportable Segment                
Segment Reporting Information [Line Items]                
Revenues 529     1,339     13,032 4,597
Research and development employee expense, lab supplies and overhead 3,194     6,166     9,927 20,174
Imdusiran IM-PROVE I, II & III clinical trials expense 1,073     5,031     4,862 14,430
AB-101-001 Phase 1a/1b clinical trial expense 1,134     2,931     4,771 8,927
Other early research and development programs expense 377     145     675 1,696
General and administrative 3,044     4,537     12,204 17,396
Restructuring costs 98     3,625     12,636 3,625
Other segment expense 303     367     893 857
Interest income 952     1,746     3,191 5,120
Net Income (Loss) $ (7,742)     $ (19,717)     $ (29,745) $ (57,388)
Consolidated net loss (7,742)     (19,717)     (29,745) (57,388)